# Satish Jindal

> Satish Jindal is a seed investor at Advent Life Sciences backing Biotechnology and Biopharma. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Advent Life Sciences](https://shizune.co/investors/profile/advent-life)
- Location: Cambridge, United States
- Total investments: 2
- Last investment: Oct 2024
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/satish-jindal-34a987
- X (Twitter): https://twitter.com/jindals1 
- Website: https://x.com/jindals1 
- Facebook: https://www.facebook.com/satish.jindal.355

Satish Jindal is a General Partner at Advent Life Sciences. He previously worked at Antolrx Pharmaceuticals as a Board Member and Co-founder. Satish Jindal attended the Massachusetts Institute of Technology.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Biopharma | 1 | 50% |
| Life Science | 1 | 50% |
| Therapeutics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series A | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Epitopea | Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. | $31M | Seed | Oct 24, 2024 |  |
| Amphista Therapeutics | Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins. | $7.5M | Series A | Apr 07, 2020 |  |

2 of 2 investments shown.

## Co-investors
- [adMare Bio Innovations](https://shizune.co/investors/profile/admare-bio-innovations) — VC Fund, 1 deal together
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 1 deal together
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 1 deal together
- [CTI Life Sciences Fund](https://shizune.co/investors/profile/cti-life-sciences-fund-2) — VC Fund, 1 deal together
- [European Investment Fund](https://shizune.co/investors/profile/european-investment-fund) — VC Fund, 1 deal together
- [Fonds de solidarité FTQ](https://shizune.co/investors/profile/fonds-de-solidarit-ftq) — VC Fund, 1 deal together

## About Advent Life Sciences

VC Fund · London, United Kingdom

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

5 contacts available at Advent Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew J Wood | Venture Partner | https://shizune.co/investors/profile/andrew-j-wood |
| Dale Pfost | General Partner | https://shizune.co/investors/profile/dale-pfost |
| Kaasim Mahmood | General Partner | https://shizune.co/investors/profile/kaasim-mahmood |
| Satish Jindal | General Partner | https://shizune.co/investors/profile/satish-jindal |
| Shahzad Malik | General Partner | https://shizune.co/investors/profile/shahzad-malik |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Satish Jindal invest in?

Satish Jindal invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Satish Jindal last invest?

The most recent investment recorded for Satish Jindal closed in Oct 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co